Cathy Robertson examines whether the International Air Transport Association's (IATA) CEIV Accreditation will be enough to persuade pharma's sea freight backers to consider air transportation.
There can be no doubting that the world is a changing place, with major political upheaval taking place in both the USA and Europe. Thankfully, the pharmaceutical logistics world tends to favour evolution over revolution but that does not mean that it is not an industry full of innovators.
This week leaders within temperature controlled logistics are gathering at the Excel in London to shape the future of the industry and discuss the best practise measures that will take the market forward.
This week the clinical trial supply industry gathered to discuss the future of the industry and exchange ideas to aid innovation and best practice.
In the first article of this series, we introduced the first three of our key learnings from implementing artwork improvement projects: Compelling urgency, sponsorship and vision. In this next article in the series, we will look at the next four key learnings.
Now OCEASOFT goes a step further. Our innovative automatization tools drastically reduce the required workload to set up the temperature logging of your shipping as well as the data collection. OCEASOFT solutions fasten, simplify and optimize cold chain monitoring management at key steps of the pharmaceutical supply chain.
When it comes to pharma-logistics real supply chain collaboration is about a lot more than box-ticking and endless rounds of meetings and workshops. True collaboration requires cultural change and this is where things get tricky.
Samir Sawli, PhD., CEO of Health Executive Expert at hexpert.sharepoint.com presents a case scenario he encountered with outpatient clinics and their vaccine refrigeration.
The world of Pharma Logistics didn't take its foot off the gas as the year drew to a close. The fourh quarter of 2016 saw prospects grow stronger for the launch of a debut composite refridgerated trailer in North America, new guidelines from the EMA and an investigation into a suspected pharma supply chain breach.
In the previous article we looked at the development of standard solutions, the need for appropriate levels of resourcing, provision of the right leadership and the need to stay abreast of the continually evolving legislation. In this, the final article in this series, we look at the remaining three learning points – the involvement of local country teams, getting an end-to-end solution working early and the non-legislative benefits of serialisation.